 |
 Play Video: The Importance of Insider Buying
|
|
|
| Date | Insider | Price | Amount |
|---|
12-21-2011
Insider Buy |
Theron Edwin Odlaug
Director |
$0.53
CAGR »
|
$5,300.00
10,000 shares |
12-21-2011
Insider Buy |
Gregory T. Mayes,
VP, Corp Development and GC |
$0.53
CAGR »
|
$1,050.00
2,000 shares |
12-21-2011
Insider Buy |
Nozer Mehta
VP, Biological R&D |
$0.54
CAGR »
|
$749.00
1,400 shares |
12-21-2011
Insider Buy |
Eiref Zvi
Director |
$0.53
CAGR »
|
$5,275.00
10,000 shares |
12-21-2011
Insider Buy |
Thomas J. Sabatino Jr.
Director |
$0.63
CAGR »
|
$62,880.00
100,000 shares |
12-21-2011
Insider Buy |
Joel A. Tune
Director |
$0.56
CAGR »
|
$8,475.00
15,000 shares |
12-21-2011
Insider Buy |
Jenene D. Thomas
VP of Investor Relations |
$0.53
CAGR »
|
$1,050.00
2,000 shares |
12-21-2011
Insider Buy |
Roxanne Tavakkol
VP, Global Regulatory Affairs |
$0.64
CAGR »
|
$952.50
1,500 shares |
12-21-2011
Insider Buy |
Ashleigh Palmer
President & CEO |
$0.53
CAGR »
|
$5,287.50
10,000 shares |
12-21-2011
Insider Buy |
Advanced Life Sciences Holdings, Inc.
Director |
$0.53
CAGR »
|
$5,300.00
10,000 shares |
12-21-2011
Insider Buy |
Paul Shields
Vice Pres. Mfg. Operations |
$0.53
CAGR »
|
$1,050.00
2,000 shares |
12-21-2010
Insider Buy |
Eiref Zvi
Director |
$0.73
CAGR »
|
$10,900.00
15,000 shares |
12-17-2010
Insider Buy |
Richard N. Levy
Director |
$0.70
CAGR »
|
$70,542.00
101,100 shares |
9-20-2010
Insider Buy |
Ashleigh Palmer
President & CEO |
$0.70
CAGR »
|
$6,160.00
8,800 shares |
9-21-2010
Insider Buy |
William Jacob Steinhauer
Vice President of Finance |
$0.69
CAGR »
|
$3,450.00
5,000 shares |
9-3-2010
Insider Buy |
Richard N. Levy
Director |
$0.72
CAGR »
|
$3,600.00
5,000 shares |
9-3-2010
Insider Buy |
Peter Slusser
Director |
$0.75
CAGR »
|
$1,500.00
2,000 shares |
Also See: SEC filings
Below we present the annualized performance delivered by UGNE stock since 12-21-2011 (the date of the most recent
insider purchase). The performance of the investment from the time UGNE insider buying occurred is the ultimate
test of whether insiders were right about UGNE being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
12/22/2011 |
|
| End date: |
07/03/2013 |
|
| Start price/share: |
$0.55 |
|
| End price/share: |
$0.01 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-98.18% |
|
| Average Annual Total Return: |
-92.73% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$181.78 |
|
| Years: |
1.53 |
|
UGNE Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent UGNE insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
|
|
Free UGNE Email Alerts:
